Sage Therapeutics Inc (NAS:SAGE)
$ 7.31 -0.19 (-2.53%) Market Cap: 446.28 Mil Enterprise Value: -189.95 Mil PE Ratio: 0 PB Ratio: 0.71 GF Score: 56/100

SAGE Therapeutics Inc Corporate Call - ECNP Encore Presentation: Zuranolone Data Review Transcript

Oct 04, 2021 / 12:00PM GMT
Release Date Price: $44.35 (-2.08%)

Oct 04, 2021 / 12:00PM GMT
Presentation: Zuranolone Data Review
Oct 04, 2021 / 12:00PM GMT

=====================
Corporate Participants
=====================
* Barry E. Greene
Sage Therapeutics, Inc. - President, CEO & Director
* Helen Rubinstein
Sage Therapeutics, Inc. - IR Officer
* Jim Doherty
Sage Therapeutics, Inc. - Chief Research Officer
* Stephen J. Kanes
Sage Therapeutics, Inc. - Chief Medical Officer

=====================
Conference Call Participants
=====================
* Andrea R. Tan
Goldman Sachs Group, Inc., Research Division - Research Analyst
* Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst
* Joon So Lee
Truist Securities, Inc., Research Division - VP
* Kathryn Smith
Stifel, Nicolaus & Company, Incorporated, Research Division - Associate
* Laura Kathryn Chico
Wedbush Securities Inc., Research Division - SVP of Equity Research
* Madhumita Yennawar
SVB Leerink LLC, Research Division -

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot